Thermo Fisher Scientific Acquires Olink Holding AB

Thermo Fisher Scientific Acquires The Binding Site Group

October 31, 2022

Medical Devices

Thermo Fisher Scientific has entered into a definitive agreement to acquire The Binding Site Group from a shareholder group led by Nordic Capital for £2.25 billion (about $2.6 billion). The Binding Site, a Birmingham-based specialist in protein and blood-cancer diagnostics with more than 1,100 employees and ~10% annual revenue growth, will join Thermo Fisher's Specialty Diagnostics segment to expand its capabilities in cancer diagnostics and monitoring.

Olink Proteomics Acquires Agrisera AB

May 12, 2020

Biotechnology

Olink Proteomics AB has acquired Agrisera AB, a Swedish antibody producer, to accelerate development and in‑house production of antibodies for Olink’s PEA immunoassay portfolio. The deal secures supply, lowers cost for customers, and expands Olink’s assay development capabilities by integrating Agrisera’s high-throughput antibody production.

Thermo Fisher Scientific Acquires PPD, Inc.

December 8, 2021

Healthcare Services

Thermo Fisher Scientific completed the acquisition of PPD, Inc. for $17.4 billion in cash, plus the assumption of approximately $3.0–$3.5 billion of net debt. The deal brings PPD's global clinical research and laboratory services into Thermo Fisher's Laboratory Products and Services segment, expanding Thermo Fisher's capabilities in clinical development and expected to generate approximately $125 million of synergies by year three.

PerkinElmer Acquires BioLegend for Approximately $5.25 Billion

July 26, 2021

Biotechnology

PerkinElmer, Inc. agreed to acquire BioLegend, a leading developer of antibodies and life-science reagents, for approximately $5.25 billion in cash and stock. The acquisition expands PerkinElmer's life-science franchise into high-growth areas such as biologics, cell and gene therapy, and proteogenomics, and is expected to be accretive to earnings.

Thermo Fisher Scientific Acquires Solventum's Purification & Filtration Business

September 2, 2025

Manufacturing

Thermo Fisher Scientific completed the acquisition of Solventum's Purification & Filtration business for approximately $4.0 billion in cash. The divested business—now Thermo Fisher's Filtration and Separation business—adds bioprocessing filtration, industrial filtration and membrane technologies to Thermo Fisher's Life Sciences Solutions portfolio and is expected to generate about $750 million in revenue in 2025.

CELLINK AB Acquires MatTek Corporation

March 22, 2021

Biotechnology

CELLINK AB (publ) acquired MatTek Corporation, a U.S. developer of advanced in‑vitro 3D human tissue models, completing the transaction on March 22, 2021 for approximately USD 72 million (including adjustments). The consideration included ~USD 13.6 million paid in newly issued CELLINK series B shares with the remainder paid in cash; Fairmount Partners advised MatTek on the sale.